Fulltext

Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis

Lan YW 1 , Choo KB 2 , Chen CM 3 , Hung TH 4 , Chen YB 5 , Hsieh CH 6 Show all authors , Kuo HP 7 , Chong KY 8

Affiliations 

  • 1 Division of Biotechnology, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, Republic of China. [email protected]
  • 2 Department of Preclinical Sciences, Faculty of Medicine and Health Sciences and Centre for Stem Cell Research, Universiti Tunku Abdul Rahman, Selangor, Malaysia. [email protected]
  • 3 Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan, Republic of China. [email protected]
  • 4 Division of Biotechnology, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, Republic of China. [email protected]
  • 5 Institute of Biotechnology, National Taiwan University, Taichung, Taiwan, Republic of China. [email protected]
  • 6 Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, Republic of China. [email protected]
  • 7 Department of Thoracic Medicine, Pulmonary Disease Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan, Republic of China. [email protected]
  • 8 Division of Biotechnology, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, Republic of China. [email protected]
Stem Cell Res Ther, 2015;6:97.
PMID: 25986930 DOI: 10.1186/s13287-015-0081-6

Abstract

Idiopathic pulmonary fibrosis is a progressive diffuse parenchymal lung disorder of unknown etiology. Mesenchymal stem cell (MSC)-based therapy is a novel approach with great therapeutic potential for the treatment of lung diseases. Despite demonstration of MSC grafting, the populations of engrafted MSCs have been shown to decrease dramatically 24 hours post-transplantation due to exposure to harsh microenvironments. Hypoxia is known to induce expression of cytoprotective genes and also secretion of anti-inflammatory, anti-apoptotic and anti-fibrotic factors. Hypoxic preconditioning is thought to enhance the therapeutic potency and duration of survival of engrafted MSCs. In this work, we aimed to prolong the duration of survival of engrafted MSCs and to enhance the effectiveness of idiopathic pulmonary fibrosis transplantation therapy by the use of hypoxia-preconditioned MSCs.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications